Metabolic Syndrome in Patients With Schizophrenia
Tuula Heiskanen, MD; Leo Niskanen, MD, PdD; Riitta Lyytikäinen, RN; Pirjo I. Saarinen, MD, PhD; and Jukka Hintikka, MD, PhD
J Clin Psychiatry 2003;64(5):575-579
© Copyright 2018 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Our aim was to study the frequency
of metabolic syndrome and associated factors in patients with
schizophrenia.
Method: The study group consisted of 35
outpatients with long-term schizophrenia defined by DSM-IV
criteria. Patients were assessed for the presence of metabolic
syndrome, which was defined by the criteria of the National
Cholesterol Education Program. All patients were on antipsychotic
medication. Data were collected from Jan. 1, 2001, to Aug. 30,
2001.
Results: Metabolic syndrome was found in 37% (N
= 13) of the patients, and it was associated inversely with the
total daily dose of, but not with any specific type of,
antipsychotic drug.
Conclusion: The results suggest that metabolic
syndrome is common among patients with schizophrenia, and it may
be far more common than in general populations.